Agoracom Blog Home

Posts Tagged ‘CBD’

Health Canada Gives Green Light to Tetra Bio-Pharma’s $TBP.ca #Cannabis Vs. #Fentanyl Trial $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:18 AM on Thursday, August 9th, 2018

  • Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain
  • The clinical trial will be conducted by Montreal-based Santé Cannabis, a medical clinic and contract research organization specialized in clinical research for cannabis – based therapies

Patient recruitment to begin for landmark research

ORLEANS, Ontario, Aug. 09, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain.  The clinical trial will be conducted by Montreal-based Santé Cannabis, a medical clinic and contract research organization specialized in clinical research for cannabis – based therapies.

The trial will assess the time-to-relief in patients suffering from breakthrough cancer pain.  Based on its clinical data, Tetra believes that the pharmacodynamic properties of PPP001 may provide a novel faster acting alternative to the opioid fentanyl.  In addition, the time-to-maximal plasma concentrations of THC suggest that PPP001 will provide rapid relief to the patient’s suffering.  As a prescription drug with a Drug Identification Number (DIN) PPP001 will be eligible for insurance coverage, making the cannabis-based medication accessible in pharmacies thereby providing much easier access.

The Opioid Crisis

There have been numerous news reports in the North America media highlighting the fact that we are experiencing an opioid crisis. In June, the Canadian government asked drug makers to stop marketing opioids, but for patients suffering from uncontrolled pain, this news does not provide them with an alternative to alleviate their pain.

  • There were 41,997 opioid-related deaths in the USA in 2016 contributing to the U.S. President’s declaration that the U.S. is experiencing an opioid crisis.
  • 92% of the 3,987 apparent opioid-related deaths in Canada in 2017 were accidental.
  • Males make up 76% of these fatalities; more than one-third among those aged 30-39.
  • The percentage of these accidental deaths involving fentanyl rose from 55% in 2016 to 72% in 2017.

“Medical cannabis may help reduce the use of drugs like fentanyl for treating breakthrough and chronic pain. However, unrefuted scientific data on its safety and effectiveness that will satisfy regulators, professional groups and insurers is what’s missing,” said Dr. Guy Chamberland, Interim CEO and Chief Scientific Officer of Tetra Bio-Pharma.  “Tetra is in the business of providing that evidence which would see our drug PPP001 become a complementary prescription therapy.  We’ve taken a pharmaceutical pathway of drug development involving collaborative dialogue with Health Canada and the FDA to bring cannabis and cannabinoid products to market so that physicians, who have been hesitant to recommend it, will have a new, trusted therapeutic option for their patients.”

Cannabis versus Fentanyl Clinical Trial Recruitment
Santé Cannabis will begin recruitment for the clinical trial as of October 2018. More information on eligibility criteria as well as the details and duration of the trial can be obtained by visiting the Santé Cannabis website: www.santecannabis.ca/en/research/cannabis-clinical-trial/ or by calling 514-419-4131 and select English and press 5 to reach the research team.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

About Santé Cannabis
Established in Montreal, Quebec in 2014, Santé Cannabis is a Centre of Excellence in medical cannabis research, clinical practice and healthcare professional training. Since its inception, Santé Cannabis has provided medical assessment, education, monitoring and follow-up to 5,000 patients referred by more than 2,000 Quebec physicians. Santé Cannabis operates within the guidelines for the authorization of medical cannabis as set out by the Collège des médecins du Québec.   As an independently credentialed clinical trial research organization, and with unparalleled clinical experience supporting both patients and healthcare professionals, Santé Cannabis has established itself as a global leader in medical cannabis research. Santé Cannabis is currently conducting a Health Canada approved Phase 3 trial for PPP001 for advanced cancer patients suffering from uncontrolled pain and associated symptoms, as well as a Phase 2 trial for PPP005 investigating the use of oral capsules of cannabis oil for the treatment of chronic pain.

For more information visit:  www.santecannabis.ca

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact:
energi PR
Stephanie Engel
[email protected]
514-288-8500 ext. 209
416-425-9143 ext. 209

Tetra Bio-Pharma’s $TBP.ca Dr. Chamberland to Announce Health Canada’s Green Light for the #Cannabis vs. #Fentanyl Trial $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:26 PM on Wednesday, August 8th, 2018

Logo tetrabiopharma rgb web

  • Announced that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain
  • Dr. Guy Chamberland, Interim CEO and Chief Scientific Officer will provide additional details on TVA’s Gatineau 6:00 p.m. ET News Program

ORLEANS, Ontario, Aug. 08, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain. Dr. Guy Chamberland, Interim CEO and Chief Scientific Officer will provide additional details on TVA’s Gatineau 6:00 p.m. ET News Program. A more detailed press release will be issued tomorrow.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact:
energi PR
Stephanie Engel
[email protected]
514-288-8500 ext. 209
416-425-9143 ext. 209

Tetra Bio-Pharma $TBP.ca Provides Extension to North Bud Farms $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:30 AM on Friday, August 3rd, 2018

Logo tetrabiopharma rgb web

  • Announced that the company has provided an extension to North Bud Farms Inc
  • Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc

ORLEANS, Ontario, Aug. 03, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that the company has provided an extension to North Bud Farms Inc.  Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the final receipt of North Bud’s prospectus’.  As one of the closing conditions to the sale these documents must now be submitted by August 31, 2018.  Upon final receipt of North Bud’s prospectus and meeting the requirements requested by the Ontario Securities Commission, Tetra will announce the record date and begin the process with the distribution of the dividend which must be finalized before listing the shares of North Bud Farms Inc.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

$APPB Applied BioSciences Eagerly Awaiting Hightimes IPO $HTIM

Posted by AGORACOM at 1:26 PM on Wednesday, August 1st, 2018

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

 

  • Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00
  • HTIM anticipates a total raise of $50 million
  • Former Mexican President Vicente Fox set to join High Times Board of Directors
  • Experts predict cannabis industry will grow to $20 Billion by 2020
  • Applied BioSciences is uniquely poised to recieve a return on investment.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedicbd & @therpet
Twitter @remedishop & @therpet

FULL DISCLOSURE: AppliedBiosciences is an advertising client of AGORA Internet Relations Corp.

FEATURE: Applied Biosciences – Poised to Succeed in CBD Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM at 12:43 PM on Tuesday, July 31st, 2018

        

  • Consumer company with Multiple CBD Brands focused on Consumer, Pet, Female and Health and Wellness
  • Building brand with a scalable process and operation
  • Commenced sales of its hemp-derived CBD products on LeafLink’s industry-leading B2B e-commerce platform
  • Launched CBD product line under the Remedi CBD brand
  • Products will be sold on Remedi’s new website (www.remedishop.com) and in select locations in the U.S.
  • Launched CBD product line under TherPet brand (https://therpet.com/)
  • Currently shipping to the majority of US states and Internationally to 5 countries
  • Several strategic partnerships and investments currently in place
  • Partners include: High Times & GemmaCert

Key Market Drivers

     Increasing Momentum Towards Legalization

  • Especially related to medical -use Cannabis
  • Cannabis is legal in 29 states and the District of Columbia in some form ( or decriminalized )
  • International Opportunities: * Cannabis is now trading globally, with Canadian grown Medical cannabis being exported to Germany, Croatia, New Zealand, Brazil and Chile. The Dutch are sending shipments of medical cannabis to Italy, Germany and Finland.   

     Shifting Public Opinion

  • Belief that the growth of the regulated cannabis industry has been fueled by changing public attitudes in the United States. A 2015 poll by Harris found 81% of Americans support the legalization of cannabis for medical use. Driven in part by this shift in public opinion.       

                        

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedicbd & @therpet
Twitter @remedishop & @therpet

INTERVIEW: Applied BioSciences $APPB.ca Discusses CBD and Pet health space $CGRW $APH.ca $GBLX $ACG

Posted by AGORACOM-JC at 11:51 AM on Wednesday, July 18th, 2018

Senate passes #cannabis legalization bill in final vote #Canada $N.ca $NXTTF $TBP.ca $MCOA

Posted by AGORACOM-JC at 10:16 AM on Wednesday, June 20th, 2018
  • Senate has voted to pass Bill C-45, the government’s legislation to legalize cannabis, meaning that recreational marijuana will soon be legal across Canada
  • Some parliamentarians are calling it an “historic” moment in this country, while others are warning of the work left to be done: raising public awareness about the implications of this incoming major social policy change.

Rachel Aiello, Ottawa News Bureau Online Producer

Published Tuesday, June 19, 2018 4:21PM EDT

Last Updated Wednesday, June 20, 2018 9:45AM EDT

OTTAWA — The Senate has voted to pass Bill C-45, the government’s legislation to legalize cannabis, meaning that recreational marijuana will soon be legal across Canada.

Some parliamentarians are calling it an “historic” moment in this country, while others are warning of the work left to be done: raising public awareness about the implications of this incoming major social policy change.

After more than a year of intensive study in both the House and Senate, the bill cleared the final legislative hurdle Tuesday evening, passing by a vote of 52 to 29 with two abstentions from the Independent Senators from Quebec: Sen. Marie-Françoise Mégie and Sen. Rosa Galvez.

Complete coverage on CTVNews.ca

Sen. Claude Carignan, leader of the opposition in the Senate, speaks to reporters in the Senate foyer on Parliament Hill in Ottawa on Tuesday, June 19, 2018. THE CANADIAN PRESS/Justin Tang

The vote was on a motion from Sen. Peter Harder, the Government Representative in the Senate, to accept the government’s position on the Senate’s amendments and pass the bill as is. It was all that was left in a short round of legislative ping-pong spurred by the upper chamber amending the government legislation.

The House of Commons will be notified of the Senate’s decision. After that, all that is left will be Royal Assent to officially pass the bill and for the government to determine when the new law will come into force.

Leader of the Independent Senators Group Sen. Yuen Pau Woo told reporters after the vote that the mammoth study of Bill C-45 was “a bit of a stress test” for the increasingly Independent Senate.

He said now, the work will have to begin on implementing the legislation, and making sure Canadians understand what this new regime means.

“We are now moving where in the legalized industry we have the chance to push out the illicit elements, we have the chance to do research on cannabis, we have the chance to properly educate our young people on the harms of cannabis use, and all of this should be the focus of the whole country now,” Sen. Woo said.

The legislation — an electoral promise of Prime Minister Justin Trudeau and the Liberal Party –allows adults in Canada to legally possess and use small amounts of recreational cannabis. It sets out parameters around the production, possession, safety standards, distribution, and sale of the drug. It also creates new Criminal Code offences for selling marijuana to minors. The proposed federal law spells out that it will be illegal for anyone younger than 18 to buy pot, but allows for provinces and territories to set a higher minimum age.

In a tweet, Justice Minister Jody Wilson-Raybould, who was the bill’s sponsor, and first introduced the legislation in April 2017, said it was “an historic milestone for progressive policy in Canada.”

The federal government is expected to formally respond to the bill’s passage Wednesday morning in the House of Commons foyer.

Last week, the government announced it would be accepting most but not all of the Senate’s more than 40 proposed amendments to Bill C-45. Among the 13 amendments that the federal Liberals rejected were the proposal to allow the provinces and territories to ban home-grown marijuana, and a proposed change to prohibit pot producers from distributing branded merchandise.

Earlier in the evening, an attempt by Conservative Sen. Claude Carignan to insist on an amendment to let provinces ban marijuana home cultivation, failed.

Reacting to his effort to push back on the government’s rejection of the change, Carignan said his attempt was to give the provinces a right he believes they should have, in an effort to circumvent what is now likely: the matter winding up in court.

Senators spent much of Tuesday offering their final thoughts on the legislation, with some expressing disappointment and frustration over MPs not accepting the Senate’s changes, and raising remaining concerns with the legislation as it stands.

Others argued that the upper chamber had done its due diligence and that it was time to concede to the will of the elected House of Commons, and pass the legislation.

In calling the vote, Senate Speaker George Furey had a slip of the tongue and called “all those in flavour” instead of “all those in favour,” sending snickers through the chamber. “It’s getting late,” Sen. Furey said.

Speaking with reporters following the vote, Sen. Harder said he was finally pausing after the manoeuvrings and the procedural wrangling to acknowledge that after a very lengthy debate, Canada is on the cusp of legalization after nearly a century of prohibition.

“It is a step in the right direction and what we now need to do is to insure as we move forward in implementation, that everybody plays their role, that everybody understands the obligations that they have and uses the opportunity of the next number of weeks to inform themselves of what a legal cannabis market means for them, their family, their communities, and the opportunities and risks that it poses,” said Sen. Harder.

So is marijuana legal? No.

The bill still needs to receive Royal Assent, which is expected as soon as tomorrow. That is the final step — essentially the Crown approving the bill. It’s overseen by Canada’s representative, the Governor General.

Once it passes, the government is expected to declare the date that legalization will come into force and be applicable.

On CTV’s Question Period, parliamentary secretary and the federal government’s point-person on pot, Bill Blair said he expects the date to be some time this September.

That window of time between when the bill passes and when it becomes federal law is to allow for the provinces, territories, municipalities, police forces, and other stakeholders to make sure their piece of the pot pie is operating in accordance with the new rules.

Blair said the date they decide on will be informed by discussions with their provincial and territorial counterparts, which have been given the ability to set regulations in their jurisdictions as to how a legalized marijuana regime will operate.

What you need to know:

Many of the decisions around how legalized marijuana is sold and used will be up to the provinces and territories. Here is what you need to know about what will be allowed:

  • The federally mandated public possession limit of 30 grams of dried cannabis has been maintained across the country, with most jurisdictions opting to keep their legal marijuana-smoking ages in line with those for drinking alcohol.
  • Bill C-45 allows individuals to grow up to four marijuana plants per residence, though some provinces, like Manitoba and Quebec, plan to ban home cultivation.
  • Provincial and territorial plans vary widely on whether you’ll be able to smoke in public.
  • Provinces and territories also differ on whether pot shops will be publicly or privately owned. For those opting for publicly owned stores, these will be operated by provincial Crown corporations that sell liquor. In some cases, provinces have even created subsidiaries of these companies with names. Unless otherwise noted, these will be standalone stores wholly separate from those that sell alcohol.
  • While dried cannabis and cannabis oil — both of which will be sold in 2018 — can be used to make edible products at home, the federal government has said that packaged edible products won’t be commercially available.

For a comprehensive rundown of how each province is approaching legalized marijuana, click here.

Outcome of drug-impaired driving bill pending

Bill C-45 was introduced alongside Bill C-46 which specifically deals with impaired driving. The government has hoped throughout the process that the two bills would pass in close succession.

This legislation proposes changes to the impaired driving laws to give police new powers to conduct roadside intoxication tests, including oral fluid drug tests, and would make it illegal to drive within two hours of being over the legal limit.

However, the Senate amended Bill C-46 to remove the provision that allowed police to conduct random roadside alcohol tests. The Senate also sought to legally downgrade impaired driving offences so that they are not classified as “serious criminality” in order to protect foreign nationals and permanent residents from losing their statuses or becoming inadmissible to Canada after such a conviction.

On Monday, the government gave notice of its position on the Senate changes, stating that it “respectfully disagrees” with these two changes. However, in the motion the government indicates it is willing to accept a handful of other Senate amendments to the legislation.

The House has yet to send this message back to the Senate but once that occurs, Bill C-46 is in for a similar final debate and vote, as seen with Bill C-45, where senators will have to decide whether they insist, or accept and pass the bill.

The House of Commons is scheduled to adjourn for the summer on Friday, June 22, but the Senate is set to sit for a week longer. There is always the potential of an early adjournment, or the opportunity to sit longer in exceptional circumstances.

Source: https://www.ctvnews.ca/politics/senate-passes-cannabis-legalization-bill-in-final-vote-1.3980234

$APPB Applied BioSciences Launches Patented New Product CanaGel(TM) $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM at 9:45 AM on Tuesday, June 19th, 2018

 

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

  • Entered into a marketing and distribution agreement with CanaGel™ to launch their first patent-protected product, Hemp Oil Gel Melts
  • Independent lab tests show that after 2.5 minutes of contact, 80% of Phytocannabinoids were absorbed in vitro, and after just 5 minutes, virtually 100% of the nutrient-rich Phytocannabinoids were absorbed in vitro.
  • All CanaGel™ products are non-GMO, vegan, paleo, gluten-free, and sugar-free

 

LOS ANGELES, CA / ACCESSWIRE / June 19, 2018 / Applied BioSciences Corp. (OTCQB: APPB) (the “Company”), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, today announced that the Company has entered into a marketing and distribution agreement with CanaGel™ to launch their first patent-protected product, Hemp Oil Gel Melts.

The Company continues to increase sales of hemp-derived products through its wholly owned divisions, Remedi and TherPet, and is now pleased to report that it will be adding the patented CanaGel™ Hemp Oil Gel Melts to its comprehensive suite of product offerings.

“Since all CanaGel™ products are non-GMO, vegan, paleo, gluten-free, and sugar-free, we knew that consumers would be interested in an exciting new alternative to the existing oils, capsules, edibles and chewables on the market,” commented Chris Bridges, President of Applied BioSciences Corp.

Independent lab tests show that after 2.5 minutes of contact, 80% of Phytocannabinoids were absorbed in vitro, and after just 5 minutes, virtually 100% of the nutrient-rich Phytocannabinoids were absorbed in vitro.

Per the agreement, the Company will leverage its North American and European marketing and distribution channels to assist CanaGel™ in launching its first doctor-developed product.

“We are excited to be selected by CanaGel™ as its first marketing and distribution partner,” commented JJ Southard, Vice President of Products at Applied BioSciences. “By leveraging our strength in the hemp-derived products space, we expect to make waves with what lab tests show to be one of the highest bioavailable phytocannabinoid supplements on the market.”

About CanaGel™

Developed by an internationally renowned doctor and oral surgeon, CanaGel™ was designed to be simple, convenient and effective. CanaGel™is the first ever patented gel melts with Full-spectrum Phytocannabinoid Rich Hemp oil. The innovative, patented technology used in CanaGel™ is an easy way to get your daily hemp oil that is also Organic, Gluten and Sugar Free. Learn more at https://canagel.com/.

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

All of Applied BioSciences’ products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals and essential oils to further optimize bioavailability.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]
To be added to the Applied BioSciences email distribution list, please email [email protected] with
APPB in the subject line.
Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedishop & @therpet
Twitter @remedishop & @therpet

Marijuana Company of America $MCOA Launches New CBD-Infused Cosmetic Product hempSMART(TM) Face $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:34 AM on Tuesday, June 19th, 2018

15233 mcoa

  • Announced that the company’s hempSMART™ brand has launched its revolutionary new cosmetic product, hempSMART™ Face
  • Each bottle of hempSMART™ Face is formulated with 150mg of full spectrum, non-psychoactive Cannabidiol (CBD) oil derived from the industrial hemp plant

Escondido, California–(June 19, 2018) – Marijuana Company of America, Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that the company’s hempSMART™ brand has launched its revolutionary new cosmetic product, hempSMART Face.

Each bottle of hempSMART Face is formulated with 150mg of full spectrum, non-psychoactive Cannabidiol (CBD) oil derived from the industrial hemp plant. The newly developed hempSMART topical is a nourishing facial moisturizer that combines CBD oil with a unique blend of ayurvedic herbs and botanicals that is designed to refresh, replenish, and restore your skin cells on your face.

The innovative new formula is rich in Omega 3, 6, 7 and 9, along with naturally occurring ceramides and contains synergistic ingredients such as Organic Aloe, Sabi Inchi Oil, Argan Kernel Oil, Macademia Seed Oil, Rose Hip Seed Oil, Pomegranate Seed Oil, Tulsi, Turmeric Oil, Frankinsense, Ashwaganda, Sweet Potato Root Extract, Coconut Oil, and Sea Buckthorn Oil.

MCOA’s CEO, Donald Steinberg, commented, “Our team is excited to announce the expansion of the hempSMART brand into the world of cosmetic products. HempSMART will continue to build upon our already established and unique formulations to provide our customers and affiliates with the tools needed to succeed in the wellness industry.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

NNW Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Namaste $N.ca $NXTTF enters into distribution agreement with Lowell Herb Co California’s fastest growing #cannabis brand to penetrate the Canadian recreational market $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:44 AM on Wednesday, June 6th, 2018

Namaste Technologies (CNW Group/Namaste Technologies Inc.)

  • Company has signed a supply and distribution agreement with Lowell Herb Co.
  • To launch Lowell Smokes brand of ultra-premium cannabis products for the Canadian recreational and medical cannabis markets
  • Agreement represents a strategic partnership between Namaste and Lowell Smokes to leverage Namaste’s resources and Lowell’s international brand appeal

VANCOUVER, June 6, 2018Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that the Company has signed a supply and distribution agreement (the “Agreement”) with Lowell Herb Co. (“Lowell Smokes” or “lowellsmokes.com”) to launch Lowell Smokes brand of ultra-premium cannabis products for the Canadian recreational and medical cannabis markets. In anticipation of Canada’s roll-out of legal recreational cannabis, the Agreement represents a strategic partnership between Namaste and Lowell Smokes to leverage Namaste’s resources and Lowell’s international brand appeal. Namaste will work with Lowell Smoke’s procurement team to source the highest quality cannabis grown with organic methods and facilitate packaging and distribution through the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”). Namaste anticipates a strong demand for organic cannabis products as the general consumer market becomes more conscious of the products they consume.

California is considered by many to be the most competitive cannabis brand market in the world. Lowell Smokes has established itself as one of the strongest brand names in California and within the entertainment industry and its ties to Hollywood have played a key role in supporting the brand and making it ideally suited for international expansion. In a recent BDS Analytics report, Lowell Smokes ranked as the #1 pre-roll brand in California amongst over 50 other brands listed, with an impressive 12% market share. Lowell Smokes is in over 250 top dispensaries across the entire state of California. With celebrities like N.O.R.E, Snoop Dogg, Jimmy Kimmel, Sarah Silverman, Bella Thorne, Bria Vinaite, Sasha Lane and dozens of others talking about the brand and posting content on social media, this Agreement will bring great value to Namaste and its shareholders.

With the impending roll-out of recreational cannabis in Canada, the Company believes that over time, the commoditization of Cannabis will require companies to become more innovative in branding and marketing to differentiate themselves. Namaste will continue to pursue strategic partnerships where the Company can leverage their e-commerce and technology platform to provide value to brands like Lowell Smokes.

Terms of the Agreement

  • Namaste will secure supply of high-quality cannabis and produce Lowell Smoke’s branded products on-site at Cannmart.
  • Lowell Smokes will provide packaging and branding guidelines, in compliance with Health Canada regulations.
  • Lowell Smokes will pay a monthly rental fee that will include storage and overhead costs to Cannmart.
  • Lowell Smokes will pay Namaste a 5% royalty fee for all wholesale orders sold through Cannmart.
  • Lowell Smokes will provide Namaste with wholesale prices for non-cannabis products that will be sold through Namaste’s e-commerce platform.

MANAGEMENT COMMENTARY

David Elias, President and CEO of Lowell Herb Co comments; “We are thrilled to announce our partnership with Namaste. Lowell Herb co is the fastest growing cannabis brand in California, and we believe that there is a massive opportunity for our brand internationally.  Working with Namaste, we are confident that they are the perfect partner to help us enter the Canadian market.  They have a unique offering, and they are solid operators with deep domain expertise in eCommerce.”

Sean Dollinger, President and CEO of Namaste Technologies comments; “We believe the strength of the Lowell Smokes brand makes it a perfect brand to be distributed globally. We have seen the sales data in California, the largest and most competitive market in the US, and it’s clear that customers love and adore the Lowell brand. We feel confident that the market for organic cannabis products will play an important role for Canadian consumers and that the timing is perfect for Namaste to not only help the team at Lowell take advantage of the opportunity in Canada but also to help them explore the international marketplace.

When we created the platform, our primary focus was on enhancing the customer experience and we built it with brands like Lowell Smokes in mind. We have been long-time fans of the Lowell Smokes brand and we are excited for them to be our first American brand on the platform, as we look to bring our customers the very best products the cannabis market has to offer. We believe expanding our offering will broaden our customer base and help set us apart from our competitors.”

About Lowell Herb Co.

The Lowell Herb Co is the fastest growing, most talked about cannabis brand in California and its signature product, Lowell Smokes, a pack of pre-rolls, is currently the number one selling cannabis product in California, available in over 250 dispensaries and for delivery statewide through their partnership with Eaze.  Lowell cultivates, and sources flowers grown with only organic fertilizer, never using synthetic pesticides. Vanity Fair recently described Lowell as “The California family of farms that grows organic cannabis for green-minded consumers who value premium goods and sophisticated design.”  Lowell has been featured in major media outlets including Cosmopolitan, High Times, NPR, Time Out LA, CBS News, Huffington Post, and many others.

For more information on Lowell Herb Co please visit

http://www.lowellsmokes.com/

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

For more information on Namaste Technologies please visit

NamasteTechnologies.com

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Investor Relations: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

Lowell Herb Co (CNW Group/Namaste Technologies Inc.)

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-enters-into-distribution-agreement-with-lowell-herb-co-californias-fastest-growing-cannabis-brand-to-penetrate-the-canadian-recreational-market-300660669.html

SOURCE Namaste Technologies Inc.